The FWA Front Desk Bulletin-April 2026
👋 Welcome
Real Enforcement. Real Lessons. Real World Awareness. “Your first stop to check-in for ongoing awareness”
The FWA Front Desk is a standing compliance resource designed to share recent Office of Inspector General (OIG) and Department of Justice (DOJ) enforcement actions in a clear, accessible, and practical way. Each article breaks down what happened, why regulators took action, and what lessons are most relevant for us as a Medicare Advantage Prescription Drug (MAPD) plan.
This content is intended for awareness and education purposes and is available for employees and FDR partners to access at any time.
This edition highlights a recent telemedicine fraud case, an area that continues to receive heightened regulatory scrutiny.
🔮 Looking Ahead
The FWA Front Desk will be updated regularly with new enforcement spotlights. Each article is designed to be quick to read, easy to understand, and practical- supporting shared awareness across the organization and our FDR partners.
Readers are encouraged to check back often and to contact the SIU team with questions or observations related to potential fraud, waste, or abuse.
*Denotes anonymous reporting option available
Understanding how enforcement agencies identify and address these schemes helps all stakeholders recognize risk earlier and respond more effectively.
🚨 Fraud in Focus: Telemedicine Gone Wrong
In March 2026, federal enforcement agencies announced that the owner of a telemedicine company, TelevisitMD, pleaded guilty to organizing a $46.2 million Medicare fraud scheme. The investigation was led by the Department of Justice in coordination with the HHS Office of Inspector General and the Federal Bureau of Investigation.
At a high level, the scheme misused telemedicine as a vehicle to generate medical orders at scale; orders driven by marketing strategies rather than legitimate clinical need. Medicare beneficiaries were contacted through aggressive telemarketing campaigns and encouraged to accept orthotic braces and genetic tests, often without fully understanding why these items were being offered or whether they were medically necessary.
Physicians were paid to approve orders despite lacking established patient relationships and, in many cases, without meaningful interaction with the beneficiaries themselves. Once signed, these orders were sold to durable medical equipment suppliers and laboratories, which then billed Medicare for the products and services.
Over a six‑year period, more than $46.2 million in false claims were submitted. Medicare paid approximately $17.9 million, while the telemedicine company owner personally received more than $10.4 million from the scheme. The individual pleaded guilty, agreed to restitution, and faces a potential prison sentence.
This enforcement action reflects a pattern regulators continue to see with telehealth‑related fraud. Marketing outreach occurred before any meaningful clinical evaluation. Telemedicine encounters, when documented, failed to meet Medicare requirements. Clinical judgment was replaced by high‑volume approvals, and physicians functioned as order signers rather than treating providers.
Key takeaway: When marketing activity drives care decisions instead of clinical need, fraud risk increases significantly.
🏥 Why This Matters to Our MAPD Plan
While this case involved Original Medicare, the lessons translate directly to Medicare Advantage programs. Telemedicine can improve access and convenience for members, but it also introduces risk—particularly when combined with third‑party vendors, loosely structured provider arrangements, or downstream entities with limited oversight.
CMS places responsibility on MA plans to prevent, detect, and correct fraud, waste, and abuse across their contracted networks, including First Tier, Downstream, and Related Entities. Enforcement actions like this provide valuable insight into how fraud schemes develop and where oversight breakdowns may occur.
Most large-scale fraud schemes do not begin with a single improper claim. They develop upstream through aggressive marketing, weak oversight, and the absence of meaningful clinical decision making.
🚩 What This Could Look Like in Practice
Within a Medicare Advantage environment, similar activity may surface as 1) unusually high approval rates for certain services, 2) limited documentation supporting medical necessity, or 3) providers operating across multiple states with minimal evidence of ongoing patient engagement.
Member feedback often provides early warning signs. Reports of receiving items that were never requested or not recognizing the provider associated with a service can signal broader issues. Likewise, sudden increases in specific DME or ancillary service billing—particularly when tied to a small group of ordering providers or vendors—warrant closer review.
🛡️ How We Address This Risk
Our approach to fraud, waste, and abuse focuses on prevention, detection, and correction.
Preventive efforts include clear telehealth requirements aligned with CMS expectations, strong documentation standards, and consistent oversight of vendors and FDRs. Detection relies on data analytics, monitoring of high‑risk services, and review of grievances and complaints. When issues are identified, corrective actions may range from education and repayment to contract action or referral to CMS or OIG, depending on the facts and circumstances.